First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A plus O) plus /- radiotherapy (RT): Results from the FLUORO study

被引：0
|
作者：
Chong, Geoffrey
Lee, Denise
Lee, Sze Ting
Grobler, Anneke
Khor, Richard
Campbell, Belinda A.
Thachil, Thanuja
Manos, Kate
Martynchyk, Arina
Douglas, Genevieve
Keane, Colm
Palmer, Jodie
Hawkes, Eliza Anne
机构：
[1] Grampians Hlth, Ballarat, Vic, Australia
[2] Eastern Hlth, Box Hill, Vic, Australia
[3] Austin Hlth, Dept Mol Imaging & Therapy, Heidelberg, Vic, Australia
[4] Univ Melbourne, Melbourne, Vic, Australia
[5] Olivia Newton John Canc Res Inst, Melbourne, Australia
[6] La Trobe Univ, Melbourne, Vic, Australia
[7] Murdoch Childrens Res Inst, Parkville, Vic, Australia
[8] Austin Hlth, Austin, Australia
[9] Peter MacCallum Canc Ctr, Melbourne, Australia
[10] Grampians Hlth, Ballarat, Vic, Australia
[11] Flinders Med Ctr, Adelaide, SA, Australia
[12] Univ Queensland, Frazer Inst, Brisbane, Qld, Australia
[13] Olivia NewtonJohn Canc Wellness & Res Ctr, Heidelberg, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7070
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO plus RELA) versus NIVO plus ipilimumab (NIVO plus IPI) in advanced melanoma: An updated indirect treatment comparison (ITC)
    Schadendorf, Dirk
    Tawbi, Hussein A.
    Lipson, Evan J.
    Hodi, F. Stephen
    Ascierto, Paolo Antonio
    Larkin, James
    Lao, Christopher D.
    Grob, Jean-Jacques
    Ejzykowicz, Flavia
    Palaia, Jennell
    Horton, Viviana Garcia
    Zhou, Zheng-Yi
    Christensen, Dana
    Rosenblatt, Lisa
    McDonald, Laura
    Ratto, Barbara
    Salvatore, Anthony
    Patel, Divya
    Sakkal, Leon A.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial
    Nishio, Makoto
    Barlesi, Fabrice
    West, Howard
    Ball, Simon
    Bordoni, Rodolfo
    Cobo, Manuel
    Longeras, Pascale Dubray
    Goldschmidt, Jerome, Jr.
    Novello, Silvia
    Orlandi, Francisco
    Sanborn, Rachel E.
    Szalai, Zsuzsanna
    Ursol, Grigoriy
    Mendus, Diana
    Wang, Lijia
    Wen, Xiaohui
    McCleland, Mark
    Hoang, Tien
    Phan, See
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : 653 - 664
  • [23] Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
    Piscaglia, F.
    Masi, G.
    Martinelli, E.
    Cabibbo, G.
    Di Maio, M.
    Gasbarrini, A.
    Iavarone, M.
    Antonuzzo, L.
    Mazzaferro, V.
    Ballestrero, A.
    Garufi, C.
    Bergamo, F.
    Celsa, C.
    Marino, D.
    Tovoli, F.
    Ponziani, F. R.
    Pressiani, T.
    Astolfi, C.
    Gazzoli, G. C.
    Ciardiello, F.
    Daniele, B.
    Rimassa, L.
    ESMO OPEN, 2025, 10 (02)
  • [24] IMpower133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)
    Reck, M.
    Liu, S. V.
    Mansfield, A. S.
    Mok, T. S. K.
    Scherpereel, A.
    Reinmuth, N.
    Garassino, M. C.
    De Castro Carpeno, J.
    Califano, R.
    Nishio, M.
    Orlandi, F.
    Alatorre Alexander, J. A.
    Leal, T. A.
    Cheng, Y.
    Lee, J-S.
    Lam, S.
    McCleland, M.
    Deng, Y.
    Phan, S.
    Horn, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 710 - +
  • [25] Impower133: Updated Overall Survival (OS) Analysis of First-Line (1L) Atezolizumab (ATEZO) plus Carboplatin plus Etoposide in Extensive-Stage SCLC (ES-SCLC)
    Reck, Martin
    Liu, Stephen V.
    Mansfield, Aaron S.
    Mok, Tony
    Scherpereel, Arnaud
    Reinmuth, Niels
    Garassino, Marina C.
    De Castro Carpeno, Javier
    Califano, Raffaele
    Nishio, Makoto
    Orlandi, Francisco
    Alatorre Alexander, Jorge Arturo
    Leal, Ticiana
    Cheng, Ying
    Lee, Jong-Seok
    Lam, Sivuonthanh
    Mccleland, Mark
    Deng, Yu
    Phan, See
    Horn, Leora
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 233 - 233
  • [26] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    Moehler, Markus H.
    Kato, Ken
    Arkenau, Hendrik-Tobias
    Oh, Do-Youn
    Tabernero, Josep
    Cruz-Correa, Marcia
    Wang, HongWei
    Xu, Hui
    Li, Jiang
    Yang, Silu
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
  • [27] Durvalumab (D) plus /- tremelimumab (T) plus chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON.
    Cho, Byoung Chul
    Reinmuth, Niels
    Luft, Alexander
    Alatorre-Alexander, Jorge
    Geater, Sarayut Lucien
    Trukhin, Dmytro
    Kim, Sang-We
    Ursol, Grygorii
    Hussein, Maen A.
    Lim, Farah Louise
    Yang, Cheng-Ta
    Araujo, Luiz H.
    Saito, Haruhiro
    Marotti, Miriam
    Barrett, Karen
    Shi, Xiaojin
    Peters, Solange
    Garon, Edward B.
    Mok, Tony S. K.
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [28] OBINUTUZUMAB PLUS BENDAMUSTINE VERSUS BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY FOLLICULAR LYMPHOMA: RESULTS FROM THE GADOLIN STUDY
    Trneny, M.
    Bouabdallah, K.
    Dueck, G.
    Gribben, J.
    Lugtenburg, P.
    Press, O.
    Salles, G.
    Sehn, L.
    Berge, C.
    Fingerle-Rowson, G.
    Wassner-Fritsch, E.
    Cheson, B.
    HAEMATOLOGICA, 2016, 101 : 155 - 156
  • [29] Anithracyclines based chemotherapy plus sequential rituximab as first-line therapy in follicular lymphoma: Longterm follow-up results
    Rigacci, L.
    Nassi, L.
    Mappa, S.
    Puccini, B.
    Carrai, V
    Alterini, R.
    Bernardi, F.
    Bosi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 61 - 62
  • [30] IMpower133: Primary efficacy and safety plus CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab plus carboplatin plus etoposide in extensive-stage SCLC (ES-SCLC)
    Mok, T. S. K.
    Reck, M.
    Horn, L.
    Lam, S.
    Shames, D. S.
    Liu, J.
    Kabbinavar, F.
    Lin, W.
    Sandler, A.
    Liu, S. V.
    ANNALS OF ONCOLOGY, 2018, 29
12345